Articles tagged "Monoclonal antibodies"

2022 American Transplant Congress
Use of Monoclonal Antibodies for Treatment of Solid Organ Transplant Recipients with COVID-19: A Single Center Experience
S. Anjan¹, C. Vu², A. Vega², M. Maxam², J. Bini Viotti³, Y. Natori¹, J. Simkins¹, A. Khatri³, A. Mattiazzi¹, R. Vianna¹, J. Cienki², L. Lee², G. Guerra¹, L. Abbo²
¹Miami Transplant Institute, Miami, FL, ²Jackson Health System, Miami, FL, ³University of Miami Miller School of Medicine, Miami, FL
*Purpose: The risk of severe COVID-19 requiring hospitalization and death is higher in solid organ transplant recipients (SOTr). There remains limited data on the use…
2022 American Transplant Congress
Daratumumab for Recurrence of Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits in a Post-Kidney Transplant Recipient: A Case Report
K. Progar¹, T. Alhamad², H. Murad³, A. Java⁴, A. Malone⁵, J. Gaut⁶, R. Delos Santos⁷, M. Merzkani⁸
¹Transplant, Barnes-Jewish Hospital, St. Louis, MO, ²Washington University School of Medicine at St. Louis, Saint Louis, MO, ³Transplant, Washington University, St. Louis, MO, ⁴Washington University School of Medicine in St. Louis, Saint Louis, MO, ⁵Washington University School of Medicine, Saint Louis, MO, ⁶Washington University, Saint Louis, MO, ⁷Transplant Nephrology, Washington University School of Medicine, St. Louis, MO, ⁸Transplant, Washington University School of Medicine, Saint Louis, MO
*Purpose: Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits (PGNMID) is a rare kidney disease associated with a high rate of recurrence post-kidney transplantation resulting in graft…
2022 American Transplant Congress
Fixed-Dose Rituximab for Pre-Transplant DSA in Kidney Transplant Recipients
K. Progar¹, K. Kurwicki², N. Nesselhauf³, J. Hagopian⁴, S. January⁵, H. Wijeweera⁶, M. McCloskey⁷, M. Merzkani⁸, R. Delos Santos⁹
¹Transplant, Barnes-Jewish Hospital, St. Louis, MO, ²SSM Health Saint Louis University Hospital, Saint Louis, MO, ³Barnes-Jewish Hospital, Edwardsville, IL, ⁴Pharmacy, University of Michigan, Ann Arbor, MI, ⁵Pharmacy, Barnes-Jewish Hospital, Saint Louis, MO, ⁶Washington University, Saint Louis, MO, ⁷Barnes-Jewish Hospital, St. Louis, MO, ⁸Washington University, St Louis, MO, ⁹Transplant, Washington University, St. Louis, MO
*Purpose: Donor specific antibodies (DSAs) occur in 15-30% of kidney transplant recipients (KTRs) and are associated with rejection and graft loss. Rituximab (RTX), an antiCD20…
2022 American Transplant Congress
The Addition of Bortezomib to a Rituximab Based Antibody Mediated Rejection Treatment Protocol in Lung Transplant
M. Galle, P. Stracener, K. Warrior, J. Lyons
Loyola University Medical Center, Maywood, IL
*Purpose: To evaluate the impact of antibody mediated rejection (AMR) treatment with rituximab combined with bortezomib vs. rituximab alone on patient survival, graft survival, and…
2022 American Transplant Congress
Use of Monoclonal Antibody Casirivimab-Imdevimab for Treatment of COVID-19 in Kidney Transplant Recipients
A. El Chediak, K. Bloch, R. Forbes, A. Langone, B. P. Concepcion, B. A. Sarrell
Vanderbilt University Medical Center, Nashville, TN
*Purpose: Kidney transplant recipients are at high-risk for severe coronavirus disease 2019 (COVID-19). Studies suggest that intervention with monoclonal antibody (MAB) treatment may decrease hospitalization…
2022 American Transplant Congress
A Randomized Phase 2 Study Of Mau868 Vs Placebo To Treat Bk Viremia In Kidney Transplant Recipients
S. Jordan¹, A. P. Limaye², B. Fischbach³, P. Sood⁴, S. Collette⁵, L. Gasink⁶, M. W. Fordyce⁷, C. J. Lin⁷, M. Hodges⁶, D. C. Brennan⁸
¹Cedars-Sinai Medical Center, Los Angeles, CA, ²University of Washington, Seattle, WA, ³Dallas Nephrology Associates, Inc, Dallas, TX, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada, ⁶previous employee/consultant for Amplyx Pharmaceuticals, San Diego, CA, ⁷Vera Therapeutics, Inc, Brisbane, CA, ⁸Johns Hopkins School of Medicine, Baltimore, MD
*Purpose: To assess the safety and efficacy of MAU868, a BK virus-specific monoclonal antibody, in adult kidney transplant recipients with BK viremia.*Methods: This is a…
2022 American Transplant Congress
The Impact Of Monoclonal Antibody Against Sars-CoV2 And Vaccination On Outcomes In Kidney Transplant Recipients With Covid-19
N. M. Ali, V. Tatapudi, R. Chand, k. Sureau, S. Mehta, R. Montgomery
NYU Langone Transplant Institute, New York, NY
*Purpose: Solid organ transplant recipients are at high risk of morbidity and mortality from coronavirus disease 2019 (COVID-19) with mortality rates as high as 30%…
2022 American Transplant Congress
Basiliximab Provides Similar Efficacy and Renal Recovery in Steroid-Minimal Liver Transplantation
L. Bowman¹, A. Webb¹, Y. Alsalihi², F. Fakhre³, R. Baliga⁴, V. Subramanian⁵, K. Robichaux³, S. Mohammed³, M. Gosselin⁶, J. Buggs⁵, A. Kumar⁷
¹Transplant Pharmacy, Tampa General Hospital, Tampa, FL, ²California Health Sciences University, Clovis, CA, ³University of South Florida, Tampa, FL, ⁴Florida Kidney Physicians, Tampa, FL, ⁵Transplant Surgery, Tampa General Hospital, Tampa, FL, ⁶University of Tampa, Tampa, FL, ⁷Morsani College of Medicine, University of South Florida, Tampa, FL
*Purpose: Due to nephrotoxic effects of tacrolimus, previous studies have evaluated the utility of basiliximab to delay or reduce tacrolimus for renal preservation in orthotopic…
2022 American Transplant Congress
Improved Mortality in COVID-19 Kidney Transplant Recipients Treated with Bamlanivimab
A. Hamiduzzaman, U. Reddy
Nephrology, UC Irvine, Orange, CA
*Purpose: Transplant recipients are particularly vulnerable to catastrophic sequelae of COVID-19. In an early multi-center study of 482 solid organ transplant (SOT) recipients with COVID-19,…
2021 American Transplant Congress
Desensitization Using Clazakizumab® (anti-il-6) in Highly-hla Sensitized Patients Awaiting Kidney Transplant (nct03380962)
A. A. Vo¹, N. Ammerman¹, E. Huang¹, M. Toyoda², S. Ge², A. Peng¹, R. Najjar¹, S. Sethi¹, S. Williamson¹, C. Myers¹, K. Lim¹, M. Gillespie¹, S. Jordan¹
¹Kidney Transplant, Cedars Sinai Medical Ctr, Los Angeles, CA, ²Transplant Immunology Laboratory, Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: IL-6 is a critical cytokine for plasma cell IgG production. Clazakizumab (CSL Behring LLC) is a humanized monoclonal aimed at the cytokine IL-6. Here…

1
2
3
…
5
Next Page »